Benzinga | Oct 28, 2020 08:52AM EDT

UBS Initiates Coverage On PTC Therapeutics with Neutral Rating, Announces Price Target of $55

UBS analyst Colin Bristow initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Neutral rating and announces Price Target of $55.